Literature DB >> 25595669

Change of regional choroid thickness after reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy.

Saki Manabe1, Chieko Shiragami2, Kazuyuki Hirooka1, Saeko Izumibata1, Akitaka Tsujikawa1, Fumio Shiraga3.   

Abstract

PURPOSE: To evaluate macular choroidal thickness after reduced-fluence photodynamic therapy (PDT) for chronic central serous chorioretinopathy (CSC).
DESIGN: Prospective, consecutive, interventional case series.
METHODS: Twenty-two eyes with chronic CSC were treated with reduced-fluence PDT. Macular choroidal thickness was examined using spectral-domain optical coherence tomography with a 3-dimensinonal radial scan protocol in the choroidal mode before and 1, 3, and 6 months after the treatment. The mean choroidal thickness in the Early Treatment Diabetic Retinopathy Study grid (center, inner circle, and outer circle) was compared between before and after therapy, as well as between treated eyes and 54 volunteer normal eyes.
RESULTS: Chronic CSC eyes showed significantly thicker choroids in the macular area compared with normal controls (P < .0001). After the single treatment session, subretinal fluid resolved completely in all eyes, and there were no recurrences during the study period. Choroidal thickness within the center area and inner circle showed a significant reduction at all time points after treatment (P < .05). The choroidal thickness in the outer circle showed a statistically significant reduction at 1 and 3 months but not at 6 months. After treatment, the choroidal thickness reduced to the normal values at the center and inner circle, but was still significantly thicker in the outer circle (P < .01).
CONCLUSION: Chronic CSC eyes showed significantly thicker choroids in the macular area. After reduced-fluence PDT, macular choroidal thickness became thinner within 6 months of treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25595669     DOI: 10.1016/j.ajo.2015.01.006

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.

Authors:  Ayako Yasui; Manabu Yamamoto; Kumiko Hirayama; Kunihiko Shiraki; Dirk Theisen-Kunde; Ralf Brinkmann; Yoko Miura; Takeya Kohno
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-06       Impact factor: 3.117

2.  Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis.

Authors:  Guohai Chen; Radouil Tzekov; Wensheng Li; Fangzheng Jiang; Sihong Mao; Yuhua Tong
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

Review 3.  Characteristics of Pachychoroid Diseases and Age-Related Macular Degeneration: Multimodal Imaging and Genetic Backgrounds.

Authors:  Kenji Yamashiro; Yoshikatsu Hosoda; Masahiro Miyake; Sotaro Ooto; Akitaka Tsujikawa
Journal:  J Clin Med       Date:  2020-06-29       Impact factor: 4.241

4.  Choroidal Volume Evaluation after Photodynamic Therapy Using New Optical Coherence Tomography Imaging Algorithm.

Authors:  Miki Sato-Akushichi; Shinji Ono; Gerd Klose; Youngseok Song
Journal:  Pharmaceuticals (Basel)       Date:  2021-11-10

5.  Superficial Retinal Microvasculature and Choriocapillaris Alterations after Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.

Authors:  Morteza Entezari; Iman Ansari; Alireza Ramezani; Humayoun Nikkhah; Parisa Mohammadi; Bahar Kheiri
Journal:  J Ophthalmol       Date:  2022-07-31       Impact factor: 1.974

6.  Ultra-Short-Term Reproducibility of Speckle-Noise Freed Fluid and Tissue Compartmentalization of the Choroid Analyzed by Standard OCT.

Authors:  Peter Maloca; Cyrill Gyger; Andreas Schoetzau; Pascal W Hasler
Journal:  Transl Vis Sci Technol       Date:  2015-11-17       Impact factor: 3.283

7.  Carotid Artery Endarterectomy Effect on Choroidal Thickness: One-Year Follow-Up.

Authors:  Gilad Rabina; Dana Barequet; Michael Mimouni; Yefim Rabinovitch; Yehuda Wolf; Adiel Barak; Anat Loewenstein; Shulamit Schwartz
Journal:  J Ophthalmol       Date:  2018-12-18       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.